Infused into the peripheral vein on day 5; delivered directly to the pancreas via he splenic artery using endovascular catheters on day 10
Fever, subcutaneous hematoma, and headache were observed; mild improvement in HbA1c, insulin dosage, and fasting C-peptide; markers of systemic inflammation were decreased
Subjects were randomized to receive one of the following three rexlemestrocel-L doses or placebo in a 3 : 1 ratio using a sequential, escalating dose cohort paradigm
No acute adverse events; HbA1c was reduced at all time points after week 1
Treatment was administered by intravenous infusion on day 0 following baseline assessments; two sequential dose cohorts, to receive rexlemestrocel-L or placebo; study duration was 60 weeks
No acute adverse events; improved eGFR and mGFR at week 12
The hUC-MSCs were transplanted by infusing cells/kg via the pancreatic artery directed on day 1, followed by infusing cells/kg through the peripheral vein on days 8, 15, and 22
ΔCP30/ΔG30 and AUCCP180 increased; FPG, 2hPG, HbA1c, and HOMA-IR reduced